Marisa Wexler, MS, senior science writer —

Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.

Articles by Marisa Wexler

Europe Awaits Proposed New Framework for Sharing Health Data

The European Commission is expected to propose a new governing framework for health data next month, called the European Health Data Space (EHDS), with the aim of connecting national health systems to facilitate secure and efficient transfer of data across systems in different European nations. The move is expected to…

Combining Endpoints May Better Predict PAH Survival Outcomes

Combining measures of symptom severity, physical function, and heart health can help predict survival outcomes in pulmonary arterial hypertension (PAH), according to a new study. The study, “Prognostic value of improvement endpoints in pulmonary arterial hypertension trials: A COMPERA analysis,” was published in The Journal of Heart and…

Administrative Data Can Identify PH to Aid in Disease Research

Hospital-based administrative data can be used to identify patients with pulmonary hypertension (PH) in medical records, according to a study done in Canada. These results, if validated, would pave the way for advances in the screening and treatment of PH, and help investigators improve epidemiological research into this rare…

Pulmonary Hypertension Tied to Increased Cancer Risk

People with pulmonary hypertension are at increased risk of developing cancer, especially lung and skin cancers, a new study indicates. The study, “Pulmonary hypertension is associated with an increased incidence of cancer diagnoses,” was published in the journal Pulmonary Circulation. Pulmonary hypertension (PH) refers to…

Tenax Plans Phase 3 Trial of TNX-201 for Later This Year

Tenax Therapeutics has completed a pharmacological assessment of TNX-201, the company’s new oral formulation of imatinib for pulmonary arterial hypertension (PAH), in healthy volunteers. The assessment included comparisons against Gleevec, another oral formulation of imatinib sold by Novartis that is approved to treat certain blood cancers, but was…